Safety of Intravenous Lidocaine Infusions
The purpose of this study is to prospectively determine the side effects profile in adults with neuropathic pain receiving intravenous infusions of lidocaine 5 mg per kg of lean body weight, infused over 45 minutes.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Safety of Intravenous Lidocaine Infusions for Chronic Neuropathic Pain|
|Study Start Date:||June 2009|
|Study Completion Date:||January 2010|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes
Consecutive patients from two time periods:
Adults > 18 yrs with chronic central or peripheral neuropathic pain at the St Joseph's Health Care Pain Clinic between June and December 2009.
Outcome measures: All side effects spontaneously reported. Sedation, nausea, dizziness by Visual Analog Score Q 15 minutes; hemodynamic data q 5 minutes during and after infusion for 30 minutes.
Daily diary of side effects and Visual Analogue score of Pain for 7 days post-infusion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01091935
|St Joseph's Health Care|
|London, Ontario, Canada, N6A 4V2|
|Principal Investigator:||Patricia K Morley-Forster, MD, FRCPC||Associate Professor,Dept of Anesthesia and Perioperative Medicine,University of Western Ontario, Lawson Health Research Institute|
|Principal Investigator:||Patricia K Morley-Forster, MD, FRCPC||Associate Professor, University of Western Ontario, Lawson Health Research Institute|